ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

11 links0 made here, not in the record23 judgments2 judges (the rules as one: Rule based)1 record change seen
Claude Opus 5.5Rule basedRecord updated on ClinicalTrials.govReplaced, or read an older version
Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT07010393Genotype-Driven NeoadjuvantTherapy for LocallyAdvanced Thyroid Cancer: AReal-World Cohort StudyFujian Medical UniversityPhase 4 · not yet recruitingRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Nov 8 · ClinicalTrials.gov record · MeSH filing re-derivedMeSH filing re-derivedCONDITIONSThyroid NeoplasmsThe registry's MeSH filing›As of now · Rule based · Main conditionMain conditionDRUGSDabrafenibIntervention entry›Nov 1 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedTrametinibIntervention entry›Nov 1 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedSelpercatinibIntervention entry›Nov 1 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedPralsetinibIntervention entry›Nov 1 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedLenvatinibIntervention entry›Nov 1 · Claude Opus 5.5 · TestedNov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · BackgroundTestedLarotrectinibIntervention entry›Nov 1 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedAnlotinibIntervention entry›Nov 1 · Claude Opus 5.5 · TestedNov 18 · Rule based · BackgroundTestedPembrolizumabIntervention entry›Nov 1 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundSintilimabIntervention entry›Nov 1 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedCabozantinibIntervention entry›Nov 1 · Claude Opus 5.5 · TestedNov 2 · Claude Opus 5.5 · TestedNov 18 · Rule based · BackgroundTested

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Dabrafenib

From the registry record2 judgments on this link
Role in the study, from the registry to what was judged
RegistryEntry “Dabrafenib”the record gives no role
→judged=agrees
How the 2 judgments split100%of judgments with a known value say Tested
Tested · 2

All judgments on this study

WhenLinkJudgeDecisionState
Nov 1DabrafenibClaude Opus 5.5TestedCurrent
Nov 1TrametinibClaude Opus 5.5TestedCurrent
Nov 1SelpercatinibClaude Opus 5.5TestedCurrent
Nov 1PralsetinibClaude Opus 5.5TestedCurrent
Nov 1LenvatinibClaude Opus 5.5TestedReplaced
Nov 1LarotrectinibClaude Opus 5.5TestedCurrent
Nov 1AnlotinibClaude Opus 5.5TestedCurrent
Nov 1PembrolizumabClaude Opus 5.5BackgroundCurrent
Nov 1SintilimabClaude Opus 5.5TestedCurrent
Nov 1CabozantinibClaude Opus 5.5TestedReplaced
Nov 2LenvatinibClaude Opus 5.5TestedCurrent
Nov 2CabozantinibClaude Opus 5.5TestedCurrent
Nov 8The record itselfClinicalTrials.gov recordMeSH filing re-derivedRecord change
Nov 18DabrafenibRule based · role ruleTestedAgrees
Nov 18TrametinibRule based · role ruleTestedAgrees
Nov 18SelpercatinibRule based · role ruleTestedAgrees
Nov 18PralsetinibRule based · role ruleTestedAgrees
Nov 18LenvatinibRule based · role ruleBackgroundOverridden
Nov 18LarotrectinibRule based · role ruleTestedAgrees
Nov 18AnlotinibRule based · role ruleBackgroundOverridden
Nov 18PembrolizumabRule based · role ruleBackgroundAgrees
Nov 18SintilimabRule based · role ruleTestedAgrees
Nov 18CabozantinibRule based · role ruleBackgroundOverridden
As of nowThyroid NeoplasmsRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.